Successful technology transfer of a Zika vaccine developed by Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS) to Chongqing Zhifei Biological Products Co., Ltd.

by ZIKAlliance

Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.

5th April 2017 • comment

Risk of microcephaly after Zika virus infection in Brazil, 2015 to 2016

by Jaenisch et al.

Based on the reported data from Brazil in 2015/16, this publication describes a plausible range for the risk of microcephaly in women who were infected with Zika virus during pregnancy compared to those who were not infected. The key message is that the large uncertainty around the risk estimate needs to be further investigated because of a) the possible existence of co-factors that are yet to be validated, b) the assumptions that need be made for the proportion of women who were infected during pregnancy.

10th March 2017 • comment

Funding available for the SPSAS in Arbovirology in Brazil

by ISARIC
3rd March 2017 • comment

15th International Dengue Course and ZIKAlliance WP1 meeting to be held in Cuba next August

by ZIKAlliance
2nd March 2017 • comment